(Sharecast News) - Lateral flow contract development and manufacturing organisation Abingdon Health announced the launch of Boots' own-brand saliva pregnancy self-test across the UK and online on Wednesday, in collaboration with Salignostics and Crest Medical.
The AIM-traded firm said that following the successful launch of the first two Boots-branded self-tests for iron and vitamin D deficiency on 20 March, it was introducing the first-ever saliva pregnancy test under the Boots own-brand range.
It said the new test would be available in-store and online from the spring, providing individuals with a convenient and accessible method of pregnancy testing.
Abingdon said that, with the UK pregnancy self-test market projected to reach $56.7m by 2033, the initiative represented a strategic opportunity to introduce a new product in collaboration with the UK's top health and beauty retailer.
With consumer adoption of self-tests reaching $7.89bn in 2023, Abingdon said it was well-positioned to capitalise on the trend.
The company said it had a robust pipeline of products within its CRO/CDMO offering, and was poised to further develop OEM retail relationships within the UK and Europe.
"We are delighted to announce the launch of the Boots branded saliva pregnancy test in conjunction with our partners Salignostics and Crest Medical," said chief executive officer Chris Yates.
"This launch showcases our ability to deliver innovative and disruptive private label products through our CDMO/CRO lateral flow full-service proposition with one of the most trusted UK brands - Boots."
At 1210 BST, shares in Abingdon Health were up 10.15% at 10.74p.
Reporting by Josh White for Sharecast.com.
Abingdon Healt. (ABDX)